Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Shang‐Gin Wu"'
Autor:
Shang-Gin Wu, Tzu-Hua Chang, Meng-Feng Tsai, Yi-Nan Liu, Yen-Lin Huang, Chia-Lang Hsu, Han-Nian Jheng, Jin-Yuan Shih
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 35, Iss 1, Pp 102091- (2024)
Osimertinib is an effective treatment option for patients with advanced non-small cell lung cancer (NSCLC) with EGFR activation or T790M resistance mutations; however, acquired resistance to osimertinib can still develop. This study explored novel mi
Externí odkaz:
https://doaj.org/article/0fe9a2a3fca74c738931950645a3cfe1
Autor:
Yi-Ling Chen, Yi-Nan Liu, Yen-Ting Lin, Meng-Feng Tsai, Shang-Gin Wu, Tzu-Hua Chang, Chia-Lang Hsu, Huey-Dong Wu, Jin-Yuan Shih
Publikováno v:
Journal of Biomedical Science, Vol 30, Iss 1, Pp 1-20 (2023)
Abstract Background Metastasis is a multistep process involving the migration and invasion of cancer cells and is a hallmark of cancer malignancy. Long non-coding RNAs (lncRNAs) play critical roles in the regulation of metastasis. This study aims to
Externí odkaz:
https://doaj.org/article/67e69c5d45e84907929dff4d4ef66aef
Autor:
Tzu‐Hsiu Tsai, Chien‐Hung Gow, Yi‐Nan Liu, Meng‐Feng Tsai, Tzu‐Hua Chang, Shang‐Gin Wu, Min‐Shu Hsieh, Kang‐Yi Su, Jin‐Yuan Shih
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 14511-14525 (2023)
Abstract Objective In lung cancer patients, most deaths are caused by the distant dissemination of cancer cells. Epithelial–mesenchymal transition (EMT) and collective cell migration are distinct and important mechanisms involved in cancer invasion
Externí odkaz:
https://doaj.org/article/58e8d9efbdcb48779cafeca430fe60a8
Autor:
Yen‐Ting Lin, Chao‐Chi Ho, Wei‐Hsun Hsu, Wei‐Yu Liao, Ching‐Yao Yang, Chong‐Jen Yu, Tzu‐Hsiu Tsai, James Chih‐Hsin Yang, Shang‐Gin Wu, Chia‐Lin Hsu, Min‐Shu Hsieh, Yen‐Lin Huang, Chia‐Ling Wu, Jin‐Yuan Shih
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Introduction According to current International Association for the Study of Lung Cancer guideline, physicians may first use plasma cell‐free DNA (cfDNA) methods to identify epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
Externí odkaz:
https://doaj.org/article/16337db479754d2fa1ffefc1d301d9fd
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe MET exon 14 skipping (METex14) mutation is an important oncogenic driver in lung cancer. We performed a retrospective analysis of clinical data from lung cancer patients with the METex14 mutation to analyze their survival outcomes and
Externí odkaz:
https://doaj.org/article/dda4673d0b774d658acbb8530f02b849
Autor:
Kuei‐Pin Chung, Yen‐Lin Huang, Yi‐Jung Chen, Yi‐Hsiu Juan, Chia‐Lang Hsu, Kiichi Nakahira, Yen‐Tsung Huang, Mong‐Wei Lin, Shang‐Gin Wu, Jin‐Yuan Shih, Yih‐Leong Chang, Chong‐Jen Yu
Publikováno v:
Molecular Oncology, Vol 15, Iss 2, Pp 560-578 (2021)
Recent studies revealed the role of dynamin‐related protein 1 (DRP1), encoded by the DNM1L gene, in regulating the growth of cancer cells of various origins. However, the regulation, function, and clinical significance of DRP1 remain undetermined i
Externí odkaz:
https://doaj.org/article/d8f61843129245abb046561cff9a0983
Autor:
Yi-Nan Liu, Meng-Feng Tsai, Shang-Gin Wu, Tzu-Hua Chang, Tzu-Hsiu Tsai, Chien-Hung Gow, Hsin-Yi Wang, Jin-Yuan Shih
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 22, Iss , Pp 471-483 (2020)
Although patients with non-small cell lung cancer harboring activating mutations in the epidermal growth factor receptor (EGFR) show good clinical response to EGFR tyrosine kinase inhibitors (TKIs), patients eventually develop acquired resistance. Pr
Externí odkaz:
https://doaj.org/article/ae291da348c047c08fdb18767d657f10
Autor:
Shang-Gin Wu, Wenjing Pan, Hongna Liu, Miranda L. Byrne-Steele, Brittany Brown, Mollye Depinet, Xiaohong Hou, Jian Han, Song Li
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-12 (2019)
Abstract Background Immunology research, particularly next generation sequencing (NGS) of the immune T-cell receptor β (TCRβ) repertoire, has advanced progression in several fields, including treatment of various cancers and autoimmune diseases. Th
Externí odkaz:
https://doaj.org/article/886eb718cb1c4dacab0d1663fd0e2f35
Autor:
Shang-Gin Wu, MD, PhD, Wei-Yu Liao, MD, PhD, Kang-Yi Su, PhD, Sung-Liang Yu, PhD, Yen-Lin Huang, MD, Chong-Jen Yu, MD, PhD, James Chih-Hsin Yang, MD, PhD, Jin-Yuan Shih, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 2, Pp 100140- (2021)
Introduction: Kras mutation is the most common driver oncogene present in patients with NSCLC. Recently, the precision medicine for patients with Kras-mutated NSCLC has been under investigation, but the best treatment is still unknown. This study aim
Externí odkaz:
https://doaj.org/article/e57e98f289ae455ba7fe9760df585bcb
Autor:
Shang-Gin Wu, Chi-Lu Chiang, Chien-Ying Liu, Chin-Chou Wang, Po-Lan Su, Te-Chun Hsia, Jin-Yuan Shih, Gee-Chen Chang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
In Taiwan, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), gefitinib, erlotinib, and afatinib are served as first-line therapy for non-small lung cell cancer (NSCLC) patients with EGFR sensitizing mutations. However, t
Externí odkaz:
https://doaj.org/article/d27779be756849c6b14ccc136e8fb9c0